Who
Justin D. Gover
Director
Company insider
Files Form 4 as: Director, Design Therapeutics; Director, Xenon Pharmaceuticals; Director, COMPASS Pathways; Chief Executive Officer, Gw Pharmaceuticals.
In numbers
- Trades disclosed
- 141
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $8.2M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 20 Dec 2018
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,110 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,110 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 9 Sep 2025filed 10 Sep 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Sep 2025filed 10 Sep 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,833 at $0.00 | filing |
| 29 Jul 2025filed 30 Jul 2025 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,012 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,645 at $0.00 | filing |
| 5 Jun 2024filed 5 Jun 2024 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,542 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.